



Spravato[®] (esketamine) nasal spray: What are the risks? A guide for patients

Version 1
EM 37763/ESK/0320/009
Date of preparation: December 2020

janssen
PHARMACEUTICAL COMPANIES
OF Janssen-Cilag



▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the back of this booklet for how to report side effects.

Spravato[®] contains the active substance esketamine, which belongs to a group of medicines called antidepressants.

If you are being treated with Spravato[®], it is important that you understand the possible risks of taking this medicine. This guide will explain these risks and give you information about how you and your healthcare professional can reduce these risks.

Four risks associated with taking Spravato[®] are: dissociation, disturbances in consciousness (sedation), increased blood pressure and abuse. As well as these four risks, there are some other possible side effects of taking Spravato[®]!

If you have any questions or concerns about the risks or side effects of taking Spravato[®], talk to your healthcare professional.







Warning

**DO NOT drive or operate machinery
until the day after your Spravato®
treatment, following a restful sleep.**

Please plan to travel home on public transport, by taxi
or arrange for someone else to drive you home
after your Spravato® treatment.



2 hours



Avoid food for 2 hours before your Spravato® treatment.¹



1 hour



For 1 hour before your Spravato® treatment, avoid using any medications that are sprayed into the nose.¹



30 minutes



Avoid drink for 30 minutes before your Spravato® treatment.¹

One device contains 28 mg of Spravato®

Each device delivers two sprays (one spray in each nostril)

28 mg




One device

56 mg



Two devices

84 mg



Three devices

5 mins' rest



between using each device

How to take Spravato®

Induction phase

Twice a week



1


2

3

4

Maintenance phase

Once a week



Weeks

Once a week or once every other week (whilst prescribed)

5

6

7

8

9+

You'll need to take Spravato® twice a week for the first 4 weeks. These 4 weeks are called the **induction phase**.

After the induction phase, you'll take Spravato® once a week for 4 weeks. Then you'll take Spravato® either once a week, or once every 2 weeks. This is called the **maintenance phase**.



When is Spravato® prescribed?

Spravato® is used in adults to reduce the symptoms of depression, such as feeling sad, anxious or worthless, sleeping difficulties, change in appetite, loss of interest in favourite activities, feeling of being slowed down. It is given, together with another antidepressant, if you have tried at least two other antidepressant medicines but they have not helped.¹

Spravato® is given together with an antidepressant drug, which is taken orally (by mouth).¹ Your healthcare professional will talk to you about how to take the antidepressant and which days to take it on.

You will be supervised by a healthcare professional every time you take Spravato®.¹

How is Spravato® taken?

Spravato® is taken by a nasal spray device. Your healthcare professional will show you how to use the nasal spray. You will spray the medicine into your nose yourself.

Your healthcare professional will be there to support you when you are ready to use the nasal spray.

Doses for Spravato® are 28 mg, 56 mg or 84 mg.¹ This means you may need to use more than one nasal spray device.

Full instructions on how to take Spravato® can be found in the package leaflet. Your healthcare professional will advise you on how to take Spravato® and what dose is right for you.

Step-by-step guide to using your Spravato® nasal spray device



Step 1: Blow your nose once

Your healthcare professional will ask you to blow your nose once before using the first nasal spray.



Step 2: Sit back

Your healthcare professional will get a nasal spray device ready for use and hand it to you.

Each device contains enough Spravato® for two sprays, one for each nostril. Your healthcare professional will advise you to sit down and tilt your head back.



Step 5: Device check

After using the device, hand it back to your healthcare professional. They will check that all the medicine is gone from the device.



Step 6: Rest

Now rest for 5 minutes while leaning back slightly. Having your head tilted back will help keep the medicine in your nose. If you do feel anything dripping out of either nostril, please **do not blow your nose!** Instead, use a tissue to gently dab it.



Step 3: First nostril

Put the tip of the device straight into your nostril. The nose rest should touch the bottom of your nose. Close the opposite nostril with your finger and breathe in while pushing up the plunger. Push the plunger all the way until it stops.



Step 4: Second nostril

Repeat this process in your other nostril. You might need to switch hands to make it easier.

Take the device out of your nose and sniff gently to keep the medicine inside your nose.

If you need to use more than one device

If you need to use another device, your healthcare professional will hand you another prepared device. Use this device just like the previous one, following steps 2 to 6. **Do not blow your nose between devices.**



STEPS 2 TO 6



Step 2



Step 3



Step 4



Step 5



Step 6

Spravato[®] clinical trials



Patients with depression have taken Spravato[®] in clinical trials. All medicines are tested in clinical trials to make sure:

- They are effective at treating certain medical conditions
- We know about any side effects.

Before deciding to take Spravato[®]

Discuss the decision with your healthcare professional and raise any questions or concerns you have with them.

If you have a medical condition that affects your cardiovascular (heart and blood vessels) or respiratory (lungs and breathing) system, then you may have to be treated at a different clinic, where you can be monitored more closely. Your healthcare professional will let you know if this is the case and will explain the next steps to you.

During and after taking Spravato®

After taking Spravato®, you are asked to stay at the clinic or hospital. Your healthcare professional will make sure that you're in a relaxed and calm environment. You will be able to rest in a comfortable chair or lie down.

You may experience side effects after taking Spravato®; these tend to be short lasting (~90 minutes).²

Everyone reacts differently to medicines and some people have fewer side effects than others. These are very common (may affect more than 1 in 10 people) side effects of using Spravato®.¹

However, you may not have all or any of these:

- feeling disconnected from yourself, your thoughts, feelings and things around you
- feeling dizzy
- headache
- change in sense of taste
- feeling sleepy
- decreased feeling or sensitivity, including around the mouth area
- spinning sensation ("vertigo")
- vomiting (throwing up)
- nausea (feeling sick and wanting to throw up).

Your healthcare professional will regularly check how you're feeling and check your blood pressure.

If you are older than 65 years, you will be carefully monitored as you may be at increased risk of falling when you start moving around after treatment.

Your healthcare professional will let you know when you are ready to leave. In clinical trials, most people were ready to leave by 90 minutes after taking Spravato®.²

If you have any questions or concerns about the risks or side effects of taking Spravato®, talk to your healthcare professional.





What is dissociation?

Only some people experience dissociation after taking Spravato®.^{2,3,4} It is short lasting (~90 minutes) and can happen at any visit. It tends to become less intense over time² and can be experienced in different ways.*¹



Changes in what you see, feel and hear



A dreamlike state



Either a positive or negative experience



Distortion of time and space



Observing things from outside of yourself

In clinical trials, people who had feelings of dissociation in the first week of starting Spravato® often had them again.⁵

On the other hand, people who did not have feelings of dissociation in the first week often did not have them after future Spravato® treatments.⁵

Before taking Spravato®, your healthcare professional will make sure that you are in a calm environment.

After taking Spravato®, your healthcare professional will check how you're feeling for signs of dissociation.

Managing the risk of dissociation from Spravato®

*Dissociation and perceptual changes include transient distortions of time and space, and changes in perception of what people feel, see or hear, for example, sounds appearing louder, colours brighter or the subjective feeling of being separated from the surrounding environment or one's own body.

Dissociation Risk

How common is dissociation with Spravato®?

1 in 4 people in clinical trials told their doctor they **had feelings of dissociation.**¹



Most were **mild**
to **moderate**¹

<1 in 25 were **severe**¹

Symptoms tended to get better over time²

<1 in 100 people asked to stop taking Spravato® because of their feelings of dissociation⁶

If experiencing dissociation, you'll be checked on until the feelings have passed and you are ready to leave.

Most feelings of dissociation pass within 90 minutes.²

Who is at risk of dissociation?

You're more likely to experience dissociation if you have a history of ^{7,8}:

- post-traumatic stress disorder (PTSD)
- childhood maltreatment or a traumatic event
- eating disorders
- substance abuse (including alcohol)
- limited emotional awareness
- anxiety and mood disorders.

If you think you may have a history of any of the conditions described here, please tell your healthcare professional.

Your healthcare professional will discuss your risk of dissociation with you.





What are disturbances in consciousness (sedation)?

'Disturbances in consciousness' is a phrase used to explain a person's level of sedation, or sleepiness.⁹ This ranges from feeling slightly drowsy or lethargic, to being fully unconscious (asleep and can't be woken).¹⁰

It is unlikely that you will lose consciousness. **In clinical trials, 11 people experienced severe sedation.**¹¹ All the people who experienced sedation were able to breathe normally, had normal vital signs, and most recovered on the same day.¹

Range of sedation

No sedation



Slightly drowsy or lethargic



Fully unconscious



Managing the risk of sedation


Before taking Spravato[®], your healthcare professional will make sure it's OK for you to take Spravato[®] and that you are in a safe and secure environment.

Who is at risk of sedation?

Having some medical conditions, taking certain medications, or drinking alcohol may affect your risk of sedation.¹

Tell your healthcare professional if you have any conditions that could affect your breathing, such as Chronic Obstructive Pulmonary Disease (COPD) or sleep apnoea, or if you are extremely overweight.¹ They will discuss the risks with you and decide whether you should take Spravato[®].

⁹Including sedation; altered state of consciousness; consciousness fluctuating; depressed level of consciousness; lethargy; loss of consciousness; somnolence; sopor; stupor.
¹⁰From the TRANSFORM-1 & -2 trials.



Disturbances in consciousness (sedation) Risk

How common is sedation with Spravato®?



In clinical trials with Spravato®, **1 in 5 people** were reported to experience disturbances in consciousness.^{4,9}

Sedation usually started around 15 minutes after taking Spravato®. For most people, the level of sedation was highest 30 to 45 minutes after Spravato® was taken.¹¹



In clinical trials,[†] people who had feelings of sedation in the first week of starting Spravato® often felt this way again in Weeks 2–4 of treatment. However, sedation can occur at any visit.⁵



Most people had stopped experiencing sedation by 90 minutes after Spravato® was taken.¹

After taking Spravato®,

your healthcare professional will check for any signs of drowsiness. They do this by checking how you react to stimuli, for example saying your name, or giving you a mild shake or gentle pinch (for more severe sedation).

If you lose consciousness,

your healthcare professional will make sure that you're breathing normally and will check your reactions until you're fully awake.

Tell your healthcare professional if you are taking any medications, or have had an alcoholic drink recently, so that they will know to monitor you more closely and can decide whether you should take Spravato® at this time.



Your healthcare professional will discuss your risk of sedation with you.



What is increased blood pressure?


As blood moves around your body it pushes against the sides of your blood vessels, which is measured as your blood pressure.




Blood pressure



Blood moves around your body



An increase in blood pressure means that the force of your blood moving around your body has increased.



The biggest increase in blood pressure was seen around 40 minutes after the dose was taken.¹



For most people, blood pressure returned to normal after around 1–2 hours.¹


Most people experiencing these increases were able to continue with their Spravato® treatment.⁶

Increased blood pressure

Risk

How common is increased blood pressure with Spravato®?

In clinical trials, up to 1 in 10 people had a brief increase in their blood pressure after taking Spravato®.¹ Most blood pressure increases did not last long and were not classed as serious.¹



Who is at risk of increased blood pressure?

You cannot take Spravato® if an increase in blood pressure would pose a serious risk to your health. This includes if you have ever had certain conditions such as¹:



an aneurysm (a weak spot in a blood vessel wall where it widens or bulges out)



bleeding within the brain



if you have had a heart attack in the last 6 weeks.

Managing the risk of increased blood pressure

Your healthcare professional will check your blood pressure before and after taking Spravato®


If your blood pressure is too high to start treatment with Spravato®, your healthcare professional will talk to you about what you can do to lower your blood pressure.

Tell your healthcare professional right away if you are feeling unwell or get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures (fits) after using Spravato®.

If your blood pressure increases significantly after using Spravato® and remains high for more than a few hours, another doctor may evaluate you.

It is important to talk to your healthcare professional if you have a history of certain conditions affecting your heart, brain or blood vessels, or if you have any concerns, before taking Spravato®.





What is drug abuse?

Drug abuse happens when someone uses a medicinal product or substance for another purpose. Another medicine (ketamine), related to Spravato®, is known to be abused,¹³ so people taking Spravato® will be monitored for potential drug abuse.

Abuse: using a medical product or substance to cause a 'high'.

Drug-seeking behaviour: requesting dosing changes, asking for extra medicine, or trying to take kits from the clinic.¹²

Diversion: giving your prescribed medicines to someone they were not prescribed for.

How common is drug abuse with Spravato®?

There was no evidence of **drug-seeking behaviour**, or confirmed cases of **diversion** in clinical trials of Spravato®.¹²



Drug abuse Risk

Who is at risk of drug abuse?

You are at a higher risk of drug abuse if you have a history of¹⁴:



mental health issues



being affected by stressful environmental factors



taking addictive prescription medication



drug abuse and addiction in your family.

People with a history of drug abuse or dependence may be at greater risk for abuse and/or misuse of Spravato®.¹ Please talk to your healthcare professional if you have ever had problems with drug abuse, including prescribed medicines or illegal drugs, or with alcohol; or if you are concerned about abuse or may have a history of the conditions described here.

Managing the risk of abuse

Your healthcare professional will monitor you for any signs of Spravato® drug abuse. If they think you're at risk, they will ask you about your drug use and discuss any concerns with you.

If you have a history of substance use disorder, including alcohol, your healthcare professional will discuss this with you to make sure it's safe for you to be treated with Spravato®.





Preparation

- Your healthcare professional will discuss with you the possible risks of taking Spravato® and explain how to take the medicine
- Let your healthcare professional know if you have any pre-existing medical conditions or take any medications that may affect you taking Spravato®
- Do not eat for 2 hours, use a nasal spray for 1 hour, or drink for 30 minutes before you take Spravato®
- As you cannot drive after your Spravato® treatment, please plan to travel home on public transport, by taxi, or arrange for someone else to drive you home

Before treatment

- Your healthcare professional will make sure you are in a calm environment
- Your blood pressure will be checked to see if it is safe for you to take Spravato®
- Your healthcare professional will show you how to use the Spravato® nasal spray

This is how your healthcare professional will check you for risks and support you before, during and after Spravato® treatment

During and after treatment

- You will be able to rest in a comfortable chair or lie down
- You will spray the medicine into your nose yourself
- Your healthcare professional will monitor you for signs of any side effects
- Let your healthcare professional know if you are feeling unwell
- Your blood pressure will be checked regularly

Going home

- Your healthcare professional will check how you're feeling and agree when you are ready to leave
- Your healthcare professional may measure your blood pressure before you leave
- Spravato® can make you feel sleepy or dizzy, which can temporarily affect your ability to concentrate. Therefore, do not drive or use other machines or do anything where you need to be completely alert until the next day after a restful sleep

How to report adverse events

For additional information, please refer to the Summary of Product Characteristics (SmPC) or AM Mangion contact Medical Information by using one of the following methods:

- Phone: 00356 2397 6000
- Email: pv@ammangion.com
- Search: www.ammangion.com.mt

To report SUSPECTED ADVERSE REACTIONS, contact AM Mangion on the following:

- Phone (24/7): 00356 2397 6333
- Email: pv@ammangion.com
- Address: AM Mangion Ltd, Mangion Building, N/S Off Valletta Road, Luqa, LQA 6000, MALTA

Suspected Adverse Drug Reactions (side effects) or medication errors may be reported using the Medicines Authority ADR reporting form, which is available online at <http://www.medicinesauthority.gov.mt/adrportal>, and sent by post or email to:

- P: Pharmacovigilance Section at Post-Licensing Directorate, Medicines Authority, Sir Teri Zammit Buildings, Malta Life Sciences Park, San Gwann SGN 3000
- E: postlicensing.medicinesauthority@gov.mt

References

1. Janssen Cilag International NV, Spravato® (esketamine) Summary of Product Characteristics. DRAFT October 2019.
2. Popova V, et al. *Am J Psychiatry* 2019; 176:428–438.
3. Daly E, et al. Poster W68. American Society of Clinical Psychopharmacology (ASCP) 2018 Annual Meeting. Miami Beach, USA. 30 May 2018.
4. Ochs-Ross R, et al. *Am J Geriatr Psychiatry* 2019
5. Williamson D, et al. Poster 236. Psych Congress 2018. Orlando, USA. 25–28 October 2018
6. Wajs E, et al. Poster T67. American Society of Clinical Psychopharmacology (ASCP) 2018 Annual Meeting. Miami Beach, USA. 31 May 2018.
7. Maaranen P, et al. *Aust N Z J Psychiatry* 2005; 39:387–394.
8. Bremner JD, et al. *J Trauma Stress* 1998; 11:125–136.
9. Janssen Cilag International NV. Data on file. RF-82799.
10. American Society of Anesthesiologists. Continuum of Depth of Sedation: Definition of General Anesthesia and Levels of Sedation/Analgesia 2014. Available from: <https://www.asahq.org/standards-and-guidelines/continuum-of-depth-of-sedation-definition-of-general-anesthesia-and-levels-of-sedation/analgesia>. Accessed October 2019.
11. Janssen. Esketamine FDA advisory committee presentation 2018. Available from: <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM631430.pdf>. Accessed October 2019.
12. Janssen Cilag International NV. Data on file. RF-1/6613.
13. Liu Y, et al. *Brain Res Bull* 2016; 126:68–73
14. CASAColumbia. Addiction Medicine: Closing the Gap Between Science and Practice. June 2012. Available from: <https://www.centeronaddiction.org/addiction-research/reports/addiction-medicine-closing-gap-between-science-and-practice>. Accessed October 2019.



Notes

You can use these pages to write down any questions you have about Spravato®, and any advice your healthcare professional gives you





A series of 20 horizontal blue lines spaced evenly down the page, providing a template for writing or drawing.





A series of 20 horizontal lines for writing, arranged in a single column. The lines are evenly spaced and extend across most of the page width.





A series of 20 horizontal lines for writing, spaced evenly down the page.





